BioMarin to acquire Alesta Therapeutics for $275M upfront plus $215M milestones

BIOMARIN PHARMACEUTICAL INC

Upfront $275M cash plus up to $215M in development/regulatory milestone payments.
Gains ALE1, potential first oral therapy for hypophosphatasia (HPP), in Phase 1/2a.
Alesta spins out non-ALE1 assets and employees transfer to spinout before close.
Expected to close Q3 2026; funded with cash on hand; modestly dilutive to 2026 results.
BioMarin CEO cites strategic fit and larger rare disease market opportunity.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.